In 2011 Memorial Sloan-Kettering continued to deliver the highest-quality patient care, make major contributions to cancer research and discovery, and lay the groundwork for significant progress in the years ahead.
Work led by Memorial Sloan-Kettering scientists and physicians resulted in several significant treatment advances — in particular for metastatic melanoma and prostate cancer. Three new targeted therapies, all of which were developed by Memorial Sloan-Kettering investigators, received approval from the US Food and Drug Administration, and are changing the standard of care for these diseases.
Basic science advances in 2011 were wide-ranging. Among many accomplishments, Memorial Sloan-Kettering researchers pioneered insights into stem cell biology and its implications for translational medicine; provided a deeper understanding of how DNA integrity is maintained during cell division and reproduction; and made a breakthrough toward developing a computer method to predict a protein’s shape from its genetic sequence that could speed research in cancer and other diseases.
You can learn more about these developments, and others, in the 2011 Memorial Sloan-Kettering Annual Report.